The effect of Pentoxifylline in patients with Covid-19

Phase 3

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200705048013N1
• Lead Sponsor: Karaj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Clinical signs of fever (above 38.3 °C), dyspnea and cough
Definite diagnosis of of Covid-19 based on RT-PCR

Exclusion Criteria

Diabetes
Chronic cardiovascular disease
Obesity (with BMI higher than 30 kg/m2)
Cancer
Chronic kidney disease
End-stage renal disease with hemodialysis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxygen saturation of arterial blood. Timepoint: Before intervention, daily after intervention. Method of measurement: Pulse-oximeter monitoring.

Secondary Outcome Measures

Name	Time	Method
Mortality. Timepoint: 7, 14, 21 and 28 days after intervention. Method of measurement: Clinical examination by physician and confirmation of death.;Refer to the intensive care unit. Timepoint: 7, 14, 21 and 28 days after intervention. Method of measurement: Clinical Frailty Scale.